GLS and neoplasm: Targeting glutaminolysis with inhibitors like CB-839 (telaglenastat), a glutaminase inhibitor, has been shown to inhibit tumor progression in preclinical studies by limiting the availability of key substrates for tumor cell metabolism [167].